Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
OTCMKTS:PBSV

Pharma-Bio Serv (PBSV) Stock Price, News & Analysis

→ The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad)
Free PBSV Stock Alerts
$0.69
-0.03 (-3.52%)
(As of 02:48 PM ET)
Compare
Today's Range
$0.65
▼
$0.74
50-Day Range
$0.65
▼
$0.90
52-Week Range
$0.65
▼
$1.10
Volume
4,325 shs
Average Volume
5,575 shs
Market Capitalization
$15.73 million
P/E Ratio
22.84
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartDividendEarningsFinancialsHeadlinesSEC FilingsShort Interest

Pharma-Bio Serv MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Pharma-Bio Serv in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
37.50%
From $0.08 to $0.11 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars

See Top Rated MarketRank™ Stocks Here
PBSV stock logo

About Pharma-Bio Serv Stock (OTCMKTS:PBSV)

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.

PBSV Stock Price History

PBSV Stock News Headlines

May 18 at 8:36 PM | wsj.com
Pharma-Bio Serv Inc.
May 15, 2024 | americanbankingnews.com
Pharma-Bio Serv (OTCMKTS:PBSV) Stock Passes Below 200-Day Moving Average of $0.90
May 14, 2024 | msn.com
Körber Pharma and Siemens Take the Lead in ABI Research's MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking
May 2, 2024 | markets.businessinsider.com
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024
April 25, 2024 | markets.businessinsider.com
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
April 25, 2024 | markets.businessinsider.com
EQS-News: Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios
April 23, 2024 | markets.businessinsider.com
Biomarin Pharmaceutical earnings preview: what Wall Street is expecting
April 16, 2024 | markets.businessinsider.com
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market Expectations
April 9, 2024 | tmcnet.com
Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com's Supplier Pre-assessment Program
April 3, 2024 | benzinga.com
Looking Into Biomarin Pharmaceutical's Recent Short Interest
March 19, 2024 | finance.yahoo.com
PBSV Releases Quarterly Results
March 19, 2024 | seekingalpha.com
Pharma-Bio Serv reports Q1 results
March 4, 2024 | markets.businessinsider.com
Buy Rating Affirmed for BridgeBio Pharma Amidst Strategic Bayer Collaboration and Promising Financial Outlook
March 4, 2024 | markets.businessinsider.com
Maintaining Hold on BridgeBio Pharma Amidst Bayer Partnership and Market Uncertainties
February 26, 2024 | marketwatch.com
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update
February 23, 2024 | markets.businessinsider.com
Strong Voxzogo Performance Underpins Buy Rating for BioMarin Pharmaceutical
January 30, 2024 | finance.yahoo.com
PBSV Expands Margins and Markets
January 28, 2024 | msn.com
Jubilant Pharma Plans Stake Sale in Sofie Biosciences Amid Merger Deal
January 9, 2024 | markets.businessinsider.com
Optimistic Outlook: Buy Rating for BridgeBio Pharma with Promising Treatment Launches and Strategic Growth Drivers
January 8, 2024 | seekingalpha.com
BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
January 3, 2024 | finance.yahoo.com
PBSV Reward Shareholders with High Yield
December 21, 2023 | finanznachrichten.de
Pharma-Bio Serv Inc.: Pharma-Bio Serv Announces Special Dividend
December 8, 2023 | msn.com
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
November 28, 2023 | markets.businessinsider.com
BioMarin Pharma Reaches Agreement On Reimbursement Amount For ROCTAVIAN In Germany
November 7, 2023 | markets.businessinsider.com
Promising Future for BridgeBio Pharma: Lebovitz’s Buy Rating Backed by Potential Blockbusters and Pipeline Assets
See More Headlines

Company Calendar

Last Earnings
3/18/2024
Today
5/20/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
10/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Business Services
Industry
Management consulting services
Sub-Industry
N/A
Current Symbol
OTCMKTS:PBSV
CUSIP
N/A
CIK
1304161
Web
www.pharmabioserv.com
Phone
(787) 278-2709
Fax
787-796-5168
Employees
100
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$0.03
Trailing P/E Ratio
22.84
Forward P/E Ratio
8.56
P/E Growth
N/A
Net Income
$1.31 million
Net Margins
4.05%
Pretax Margin
5.65%
Return on Equity
3.95%
Return on Assets
3.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.10
Quick Ratio
5.10

Sales & Book Value

Annual Sales
$16.98 million
Price / Sales
0.93
Cash Flow
$0.06 per share
Price / Cash Flow
10.85
Book Value
$0.70 per share
Price / Book
0.98

Miscellaneous

Outstanding Shares
22,960,000
Free Float
20,162,000
Market Cap
$15.73 million
Optionable
Not Optionable
Beta
0.55

Key Executives

  • Mr. Victor Sanchez (Age 53)
    CEO, President & President of European Operations
    Comp: $323.67k
  • Mr. Pedro J. Lasanta (Age 64)
    CFO, VP of Finance & Administration and Secretary
    Comp: $225.6k
  • Ms. Elizabeth Plaza (Age 60)
    Founder & Senior Strategic Consultant
    Comp: $69.92k
  • Ms. Miriam Marrero M.B.A.
    Human Resources Manager

Key Competitors

View All Competitors

PBSV Stock Analysis - Frequently Asked Questions

How have PBSV shares performed in 2024?

Pharma-Bio Serv's stock was trading at $1.05 at the beginning of 2024. Since then, PBSV stock has decreased by 32.4% and is now trading at $0.71.
View the best growth stocks for 2024 here.

When is Pharma-Bio Serv's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our PBSV earnings forecast.

How were Pharma-Bio Serv's earnings last quarter?

Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.03. The company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5 million. Pharma-Bio Serv had a trailing twelve-month return on equity of 3.95% and a net margin of 4.05%.

How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv?

Pharma-Bio Serv announced a dividend on Thursday, December 21st. Investors of record on Tuesday, January 30th will be paid a dividend of $0.075 per share on Thursday, February 15th. The ex-dividend date is Monday, January 29th.
Read our dividend analysis for PBSV.

What other stocks do shareholders of Pharma-Bio Serv own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE).

How do I buy shares of Pharma-Bio Serv?

Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PBSV) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
The ONE AI Stock to own now. (It’s not Nvidia.)
Weiss Ratings
Shocking $16T Elon Musk Crypto Leak
Crypto 101 Media
The 2024 Gold Rush: Unleashing Market Potential
Priority Gold
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
Warren Buffett's "mystery stock"
Stansberry Research
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest
Elon to Transform U.S. Economy?
Porter & Company